Multifaceted role of chemokines in solid tumors: from biology to therapy

2022 ◽  
Author(s):  
Sana Raza ◽  
Sangam Rajak ◽  
Archana Tewari ◽  
Pratima Gupta ◽  
Naibedya Chattopadhyay ◽  
...  
Keyword(s):  
Solid Tumors

Practical consensus recommendations - Current role of immune response evaluation criteria in solid tumors criteria in the management of cancer patients receiving immunotherapy

2019 ◽  
Vol 4 ◽  
pp. 21-23
Author(s):  
Purvish M. Parikh ◽  
T. P. Sahoo ◽  
Randeep Singh ◽  
Bahl Ankur ◽  
Talvar Vineet ◽  
...  
Keyword(s):  
Immune Response ◽  
Solid Tumors ◽  
Evaluation Criteria ◽  
Supporting Evidence ◽  
Response Evaluation ◽  
Consensus Recommendation ◽  
Current Role ◽  
New Class ◽  
Response Evaluation Criteria

Response evaluation criteria in solid tumors (RECIST) are a method used to evaluate and document the response to cancer treatment in solid tumors. The availability of a new class of immuneoncology drugs has resulted in the need to modify RECIST criteria methodology. The first leadership immuno-oncology network (LION) master course brought together experts in oncology and immuno-oncology. Six questions were put to the experts and their opinion, supporting evidence, and experience were discussed to arrive at a practical consensus recommendation. n this nascent field, the availability of a practical consensus recommendation developed by experts in the field is of immense value to the community oncologist and other health-care consultants.

Prognostic role of high Bmi-1 expression in Asian and Caucasian patients with solid tumors: A meta-analysis

2014 ◽  
Vol 68 (8) ◽  
pp. 969-977 ◽  
Author(s):  
Yingjie Shao ◽  
Yiting Geng ◽  
Wendong Gu ◽  
Zhonghua Ning ◽  
Jingting Jiang ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Meta Analysis ◽  
Prognostic Role ◽  
Caucasian Patients ◽  
High Bmi

scholarly journals Isoform- and Paralog-Switching in IR-Signaling: When Diabetes Opens the Gates to Cancer

Biomolecules ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 1617
Author(s):  
Pierluigi Scalia ◽  
Antonio Giordano ◽  
Caroline Martini ◽  
Stephen J. Williams
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Growth Factor ◽  
Solid Tumors ◽  
Common Finding ◽  
Absolute Increase ◽  
Preferential Expression ◽  
Exon 11

Insulin receptor (IR) and IR-related signaling defects have been shown to trigger insulin-resistance in insulin-dependent cells and ultimately to give rise to type 2 diabetes in mammalian organisms. IR expression is ubiquitous in mammalian tissues, and its over-expression is also a common finding in cancerous cells. This latter finding has been shown to associate with both a relative and absolute increase in IR isoform-A (IR-A) expression, missing 12 aa in its EC subunit corresponding to exon 11. Since IR-A is a high-affinity transducer of Insulin-like Growth Factor-II (IGF-II) signals, a growth factor is often secreted by cancer cells; such event offers a direct molecular link between IR-A/IR-B increased ratio in insulin resistance states (obesity and type 2 diabetes) and the malignant advantage provided by IGF-II to solid tumors. Nonetheless, recent findings on the biological role of isoforms for cellular signaling components suggest that the preferential expression of IR isoform-A may be part of a wider contextual isoform-expression switch in downstream regulatory factors, potentially enhancing IR-dependent oncogenic effects. The present review focuses on the role of isoform- and paralog-dependent variability in the IR and downstream cellular components playing a potential role in the modulation of the IR-A signaling related to the changes induced by insulin-resistance-linked conditions as well as to their relationship with the benign versus malignant transition in underlying solid tumors.

scholarly journals Role of Bcl-3 in solid tumors

2011 ◽  
Vol 10 (1) ◽  
pp. 152 ◽  
Author(s):  
Vilma Maldonado ◽  
Jorge Melendez-Zajgla
Keyword(s):  
Solid Tumors

scholarly journals Prognostic role of tumor-infiltrating CD57-positive lymphocytes in solid tumors: a meta-analysis

Oncotarget ◽  
2017 ◽  
Vol 9 (8) ◽  
pp. 8111-8119 ◽  
Author(s):  
Guoming Hu ◽  
Shimin Wang
Keyword(s):  
Solid Tumors ◽  
Meta Analysis ◽  
Prognostic Role

scholarly journals Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review

2020 ◽  
Author(s):  
Chengliang Huang ◽  
Meizhang Li ◽  
Ben Liu ◽  
Huanbo Zhu ◽  
Qun Dai ◽  
...  
Keyword(s):  
Treatment Response ◽  
Solid Tumors ◽  
Gut Microbiome ◽  
Negative Impact ◽  
Checkpoint Inhibitors ◽  
Antibiotic Use ◽  
Underlying Mechanism ◽  
Lifestyle Factor ◽  
Therapeutic Outcomes

Abstract Background: Gut microbiome is proved to affect the activity of immunotherapy in certain tumors. However, little is known if there is universal impact on both the treatment response and adverse effects (AEs) of immune checkpoint inhibitors (ICIs) across multiple solid tumors, and whether such impact can be modulated by common gut microbiome modifiers, such as antibiotics and diet.Methods: A systematic search in PubMed followed by stringent manual review were performed to identify clinical cohort studies that evaluated the relevance of gut microbiome to ICIs (response and/or AEs, 12 studies), or association of antibiotics with ICIs (17 studies), or impact of diet on gut microbiome (16 studies). Only original studies published in English before April 1st, 2020 were used. Qualified studies identified in the reference were also included.Results: At the phylum level, patients who had enriched abundance in Firmicutes and Verrucomicrobia almost universally had better response from ICIs, whereas those who were enriched in Proteobacteria universally presented with unfavorable outcome. Mixed correlations were observed for Bacteroidetes in relating to treatment response. Regarding the AEs, Firmicutes correlated to higher incidence whereas Bacteroidetes were clearly associated with less occurrence. Interestingly, across various solid tumors, majority of the studies suggested a negative association of antibiotic use with clinical response from ICIs, especially within 1-2 month prior to the initiation of ICIs. Finally, we observed a significant correlation of plant-based diet in relating to the enrichment of “ICI-favoring” gut microbiome (P = 0.0476).Conclusions: Gut microbiome may serve as a novel modifiable biomarker for both the treatment response and AEs of ICIs across various solid tumors. Further study is needed to understand the underlying mechanism, minimize the negative impact of antibiotics on ICIs, and gain insight regarding the role of diet so that this important lifestyle factor can be harnessed to improve the therapeutic outcomes of cancer immunotherapy partly through its impact on gut microbiome.

scholarly journals Cancer-Associated Fibroblast Functions as a Road-Block in Cancer Therapy

Cancers ◽  
2021 ◽  
Vol 13 (20) ◽  
pp. 5246
Author(s):  
Pradip De ◽  
Jennifer Aske ◽  
Nandini Dey
Keyword(s):  
Cancer Therapy ◽  
Solid Tumors ◽  
Treatment Resistance ◽  
Activation Markers ◽  
Cancer Associated Fibroblast ◽  
Development Of Resistance ◽  
Origin Activation ◽  
Crucial Component ◽  
Resident Fibroblast

The journey of a normal resident fibroblast belonging to the tumor microenvironment (TME) from being a tumor pacifier to a tumor patron is fascinating. We introduce cancer-associated fibroblast (CAF) as a crucial component of the TME. Activated-CAF partners with tumor cells and all components of TME in an established solid tumor. We briefly overview the origin, activation, markers, and overall functions of CAF with a particular reference to how different functions of CAF in an established tumor are functionally connected to the development of resistance to cancer therapy in solid tumors. We interrogate the role of CAF in mediating resistance to different modes of therapies. Functional diversity of CAF in orchestrating treatment resistance in solid tumors portrays CAF as a common orchestrator of treatment resistance; a roadblock in cancer therapy.

scholarly journals Novel insights into the role of Clostridium novyi‑NT related combination bacteriolytic therapy in solid tumors (Review)

2020 ◽  
Vol 21 (2) ◽  
Author(s):  
Xu Feng ◽  
Pan He ◽  
Chen Zeng ◽  
Ye-Han Li ◽  
Sushant Das ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Clostridium Novyi ◽  
Bacteriolytic Therapy
Sign in / Sign up

Export Citation Format

Share Document